标题
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 14, Issue 9, Pages 562-576
出版商
Springer Nature
发表日期
2017-04-04
DOI
10.1038/nrclinonc.2017.40
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
- (2017) S. F. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
- (2016) Jieyi Wang et al. BMC CANCER
- A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-typeKRASwho have received first-line systemic therapy
- (2016) Cathy Eng et al. INTERNATIONAL JOURNAL OF CANCER
- MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
- (2016) F. Pietrantonio et al. Cancer Discovery
- O-008 * Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC)
- (2015) L. Rimassa et al. ANNALS OF ONCOLOGY
- c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence
- (2015) Jaudah Al-Maghrabi et al. BMC CANCER
- Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma
- (2015) Yingying Xu et al. BMC CANCER
- Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
- (2015) Wafik S. El-Deiry et al. CANCER BIOLOGY & THERAPY
- HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
- (2015) R. Carson et al. CLINICAL CANCER RESEARCH
- Clinical impact of c-MET expression and mutational status in patients with colorectal cancer lung metastases
- (2015) Thomas Schweiger et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients
- (2015) Nozomu Fuse et al. Gastric Cancer
- Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
- (2015) Yoon-Koo Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story
- (2015) Joseph A. Sparano JOURNAL OF CLINICAL ONCOLOGY
- A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.
- (2015) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).
- (2015) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials.
- (2015) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- MET is required for the recruitment of anti-tumoural neutrophils
- (2015) Veronica Finisguerra et al. NATURE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of c-Met in colorectal cancer: A meta-analysis
- (2015) Yan Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- Gastrointestinal malignancies harbor actionable MET exon 14 deletions
- (2015) Jeeyun Lee et al. Oncotarget
- Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA
- (2015) Luis A. Diaz et al. Oncotarget
- Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
- (2015) Consalvo Petti et al. Oncotarget
- A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
- (2014) Carlos Gomez-Martín et al. CANCER LETTERS
- Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
- (2014) H. Koeppen et al. CLINICAL CANCER RESEARCH
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
- (2014) J. Tabernero et al. CLINICAL CANCER RESEARCH
- MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
- (2014) Carla Boccaccio et al. CURRENT OPINION IN CELL BIOLOGY
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Reply to A. Soultati et al
- (2014) David Robert Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
- (2014) Antonio Calles et al. Molecular Oncology
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Prognostic Significance of MET Amplification and Expression in Gastric Cancer: A Systematic Review with Meta-Analysis
- (2014) Zhi Peng et al. PLoS One
- Analysis of MET mRNA Expression in Gastric Cancers Using RNA In Situ Hybridization Assay: Its Clinical Implication and Comparison with Immunohistochemistry and Silver In Situ Hybridization
- (2014) Jiwoon Choi et al. PLoS One
- c-Met Targeting Enhances the Effect of Irradiation and Chemical Agents against Malignant Colon Cells Harboring a KRAS Mutation
- (2014) Yingbo Li et al. PLoS One
- ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer
- (2014) Sandra Van Schaeybroeck et al. Cell Reports
- Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer
- (2013) Xiongyan Wu et al. CANCER LETTERS
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Expression of HGF and Met in Human Tissues of Colorectal Cancers: Biological and Clinical Implications for Synchronous Liver Metastasis
- (2013) Yan-lai Sun et al. International Journal of Medical Sciences
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
- (2013) Smita Salian-Mehta et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
- (2013) Austin M Dulak et al. NATURE GENETICS
- A colorectal cancer classification system that associates cellular phenotype and responses to therapy
- (2013) Anguraj Sadanandam et al. NATURE MEDICINE
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
- (2013) S. Corso et al. Cancer Discovery
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
- (2012) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
- (2012) Rafal Dziadziuszko et al. Journal of Thoracic Oncology
- Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer
- (2012) Alexandra Voutsina et al. MODERN PATHOLOGY
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer
- (2011) Yuji Toiyama et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- RNAscope
- (2011) Fay Wang et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- Implementing prognostic and predictive biomarkers in CRC clinical trials
- (2011) Sandra Van Schaeybroeck et al. Nature Reviews Clinical Oncology
- MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
- (2010) V. Cepero et al. CANCER RESEARCH
- A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors
- (2010) P. J. Rosen et al. CLINICAL CANCER RESEARCH
- HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
- (2010) D. Liska et al. CLINICAL CANCER RESEARCH
- A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor
- (2010) Florian Schelter et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor
- (2010) T. L. Burgess et al. MOLECULAR CANCER THERAPEUTICS
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Down-Regulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane Proteolysis
- (2009) Bénédicte Foveau et al. MOLECULAR BIOLOGY OF THE CELL
- c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
- (2008) Zhao-Shi Zeng et al. CANCER LETTERS
- Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation
- (2008) Stéphanie Kermorgant et al. JOURNAL OF CELL BIOLOGY
- HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
- (2008) T. Bachleitner-Hofmann et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started